The airways, a novel route for delivering monoclonal antibodies to treat Lung tumors

Pharmaceutical Research

Volumn 28, Issue 9, 2011, Pages 2147-2156

  Maillet, Agnès ^a   Guilleminault, Laurent ^a   Lemarié, Etienne ^a,b   Lerondel, Stéphanie ^c   Azzopardi, Nicolas ^b   Montharu, Jérôme ^d   Congy Jolivet, Nicolas ^b   Reverdiau, Pascale ^a   Legrain, Brigitte ^e   Parent, Christelle ^a   Douvin, Dominique Henri ^e   Hureaux, José ^f   Courty, Yves ^a   De Monte, Michèle ^a   Diot, Patrice ^a,b   Paintaud, Gilles ^a   Le Pape, Alain ^a,c   Watier, Hervé ^b   Heuzé Vourc'h, Nathalie ^a,g  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c TAAM CIPA UPS44   (France)

^d PPR Group   (France)

^e Laboratoires Novaxia Saint Laurent   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g INSERM   (France)

Author keywords

Aerosols; Antibodies; Carcinoma; Monoclonal; Non small cell lung

Indexed keywords

CETUXIMAB; EDETIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G;

AEROSOL; AIRWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLADDER; CANCER INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; FEMALE; GLOMERULUS; IC 50; IN VIVO STUDY; LUNG TUMOR; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NEBULIZATION; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYSTEMIC CIRCULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR MODEL;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INJECTIONS, INTRAVENOUS; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054750755     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0442-5     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96. (Pubitemid 351521864)
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-80.
3. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-smallcell lung cancer-is it becoming a reality? Nat Rev Clin Oncol. 2010;7(7):401-14.
4. Thatcher N. The place of targeted therapy in the patient management of non-small cell lung cancer. Lung Cancer. 2007;57 Suppl 2:S18-23. (Pubitemid 47188078)
5. Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, et al. Aerosolized chemotherapy. J Aerosol Med. 2008;21(1):61-70.
6. Rohrmann K, Staehler M, Haseke N, Bachmann A, Stief CG, Siebels M. Immunotherapy in metastatic renal cell carcinoma. World J Urol. 2005;23(3):196-201. (Pubitemid 41136042)
7. Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, et al. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007;13(4):1246-52. (Pubitemid 46424066)
8. Scolnik PA. mAbs: a business perspective. Mabs. 2009;1(2):179-84.
9. Reichert JM. Global antibody development trends. Mabs. 2009;1(1):86-7.
10. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol. 2008;68(2):93-106.
11. Gerber DE, Choy H. Cetuximab in combination therapy: from bench to clinic. Cancer Metastasis Rev. 2010;29(1):171-80.
12. Maillet A, Congy-Jolivet N, Le Guellec S, Vecellio L, Hamard S, Courty Y, et al. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm Res. 2007;25:1318-26.
13. Gagnadoux F, Pape AL, Lemarié E, Lerondel S, Valo I, Leblond V, et al. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J. 2005;26(4):657-61. (Pubitemid 41448664)
14. Lerondel S, Le Pape A, Sené C, Faure L, Bernard S, Diot P, et al. Radioisotopic imaging allows optimization of adenovirus lung deposition for cystic fibrosis. Hum Gene Ther. 2001;12:1-11. (Pubitemid 32044461)
15. Cézé N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. Ther Drug Monit. 2009;31(5):597-601.
16. Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, et al. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. Mabs. 2009;1(5):505-16.
17. Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 1999;14(6):451-63. (Pubitemid 30029793)
18. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004;10(19):6487-501. (Pubitemid 39346544)
19. Kang Y, Omura M, Suzuki A, Oka T, Nakagami Y, Cheng C, et al. Development of an orthotopic transplantation model in nude mice that simulates the clinical features of human lung cancer. Cancer Sci. 2006;97(10):996-1001. (Pubitemid 44322545)
20. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4):338-44.
21. Bivas-Benita M, Zwier R, Junginger HE, Borchard G. Noninvasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm. 2005;61(3):214-8. (Pubitemid 41427629)
22. Cryan SA, Sivadas N, Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev. 2007;59(11):1133-51. (Pubitemid 47628783)
23. Barrett T, Koyama Y, Hama Y, Ravizzini G, Shin IS, Jang BS, et al. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res. 2007;13(22 Pt 1):6639-48. (Pubitemid 350206799)
24. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Culabeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34(6):850-8. (Pubitemid 46798960)
25. Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm. 2008;23(2):158-71. (Pubitemid 351630188)
26. Ushiki T, Kizaka-Kondoh S, Ashihara E, Tanaka S, Masuko M, Hirai H, et al. Noninvasive Tracking of Donor Cell Homing by Near-Infrared Fluorescence Imaging Shortly after Bone Marrow Transplantation. PlosOne. 2010;5(6):e11114.
27. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and solid tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441-54.
28. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74. (Pubitemid 46020287)
29. Dumont JA, Low SC, Peters RT, Bitonti AJ. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs. 2006;20(3):151-60. (Pubitemid 43845335)
30. Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev. 2006;58(9-10):1106-18. (Pubitemid 44709269)
31. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med. 2002;196(3):303-10. (Pubitemid 34875660)
32. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by antiepidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984;44(3):1002-7. (Pubitemid 14152782)
33. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53(18):4322-8. (Pubitemid 24146785)